Ligand Pharmaceuticals LGND Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 15.3%+28.8pp | -13.5%— | —— | —— | |
| Net margin | 46.4%+48.8pp | -2.4%-42.1pp | 39.7%+56.7pp | -17%-40.7pp | |
| Returns | |||||
| Return on equity | 13.5%+14.0pp | -0.5%-8.6pp | 8%+12.7pp | -4.7%-12.2pp | |
| Return on invested capital | 4%+7.1pp | -3.1%-8.0pp | 4.9%+1.7pp | 3.3%-10.6pp | |
| Efficiency | |||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | |||||
| Current ratio | 22.2×+13.3× | 8.9×-5.2× | 14.1×+11.5× | 2.7×-8.5× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×-0.1× | 0.1×+0.1× | |
| Net debt / EBITDA | -2.3×+2.9× | -5.2×-4.9× | -0.2×-0.7× | 0.4×+0.4× | |
| Per Share | |||||
| Book value per share | $50.12+10.4% | $45.40+15.0% | $39.47+11.4% | $35.42-27.8% | |
| Valuation | |||||
| Market capitalization | $3.72B+83.8% | $2.02B+62.6% | $1.25B+10.3% | $1.13B-56.3% | |
| Price / earnings | 29.9×— | —— | 23.9×— | —— | |
| Price / sales | 13.9×+1.8× | 12.1×+2.6× | 9.5×+3.7× | 5.8×-4.9× | |
| Price / book | 3.7×+1.2× | 2.4×+0.7× | 1.8×-0.1× | 1.9×-1.3× | |
| EV / EBITDA | 47.5×-108× | 155.1×+137× | 17.8×+6.0× | 11.8×-4.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Ligand Pharmaceuticals (LGND) runs a 91.9% gross margin and a 34.5% operating margin, with a 55.9% net margin.
- Where do Ligand Pharmaceuticals's ratios come from?
- Every ratio is computed from Ligand Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.